Caberbol 0.5 (Cabergoline 0.5 mg)

Caberbol 0.5 (Cabergoline 0.5 mg) is Evolve Biolabs' long-acting dopamine agonist, supplied as 40 tablets in four blister strips of ten. It suppresses prolactin by stimulating D2 receptors in the pituitary and is one of the most researched prolactin-control compounds available.

What Caberbol 0.5 Is

Cabergoline is an ergot-derived dopamine receptor agonist with strong selectivity for the D2 subtype. Dopamine is the natural brake on prolactin secretion, so a D2 agonist reduces prolactin output from the anterior pituitary. Its defining feature is duration: the half-life is measured in days, allowing prolonged suppression from infrequent dosing. Caberbol 0.5 packages the compound at 0.5 mg per tablet, with 40 tablets across four sealed strips.

The History of Cabergoline

Cabergoline was developed by Farmitalia Carlo Erba in the 1980s and introduced as Dostinex in the 1990s for hyperprolactinaemia and prolactin-secreting pituitary tumours. It largely displaced bromocriptine because it was better tolerated and required far less frequent administration. Later research extended its use to Parkinson's disease and lactation suppression, and it remains a benchmark dopamine agonist in endocrine pharmacology.

How It Works

Cabergoline binds D2 receptors on lactotroph cells in the anterior pituitary, mimicking dopamine's inhibitory signal and reducing both the synthesis and release of prolactin. Because the drug stays bound and clears slowly, a single dose suppresses prolactin for an extended period. It is extensively metabolised in the liver and excreted in bile and urine. Acting centrally on the pituitary rather than on breast tissue, it addresses the source of prolactin production.

What the Research Shows

• Clinical trials established cabergoline's efficacy in hyperprolactinaemia and prolactinomas.
• Comparative studies show better tolerability and less frequent dosing than bromocriptine.
• Imaging research documents shrinkage of prolactinomas in a significant proportion of cases.
• Cardiac valve effects at high cumulative doses are a recognised long-term research theme.

Research Context

Cabergoline's safety literature is shaped by dose. At the low doses used for prolactin control, valve changes are rarely reported; at the much higher doses used in Parkinson's disease, cumulative exposure has been linked to fibrotic valve changes, prompting monitoring recommendations. Researchers have also examined the drug's effect on tumour size, where it can reduce prolactinoma volume. Those two strands, efficacy at low dose and risk at high dose, define the modern understanding of the compound.

Strength, Pack and Authentication

Each tablet contains 0.5 mg of cabergoline, with 40 tablets per pack arranged as four strips of ten. The tablets are sealed in moisture-resistant blisters inside a printed carton that states the active ingredient, strength and tablet count. A verification code on the packaging allows the pack to be checked against Evolve Biolabs' records.

Buying Caberbol 0.5 Online

Caberbol is one of the most searched prolactin-control products in the Evolve Biolabs range. If you are researching cabergoline, comparing Dostinex-style 0.5 mg products or looking to buy Caberbol 0.5 online from a verified Evolve Biolabs supplier, this page gives you the full specification, pack size, price and live stock status. Browse more Evolve Biolabs hormone-support products at NotNatty.